MX354653B - Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. - Google Patents
Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica.Info
- Publication number
- MX354653B MX354653B MX2014005498A MX2014005498A MX354653B MX 354653 B MX354653 B MX 354653B MX 2014005498 A MX2014005498 A MX 2014005498A MX 2014005498 A MX2014005498 A MX 2014005498A MX 354653 B MX354653 B MX 354653B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- myeloid leukemia
- protein
- transducin
- beta
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 title abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 title abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 title abstract 2
- 102000006612 Transducin Human genes 0.000 title abstract 2
- 108010087042 Transducin Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000002071 myeloproliferative effect Effects 0.000 title abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 102000015735 Beta-catenin Human genes 0.000 abstract 3
- 108060000903 Beta-catenin Proteins 0.000 abstract 3
- 230000037361 pathway Effects 0.000 abstract 3
- -1 anthracene-9,10-dione dioxime compound Chemical class 0.000 abstract 2
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003081 coactivator Effects 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556245P | 2011-11-06 | 2011-11-06 | |
| PCT/US2012/063746 WO2013067547A1 (en) | 2011-11-06 | 2012-11-06 | METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005498A MX2014005498A (es) | 2016-05-05 |
| MX354653B true MX354653B (es) | 2018-03-07 |
Family
ID=48192926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005498A MX354653B (es) | 2011-11-06 | 2012-11-06 | Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9238030B2 (https=) |
| EP (1) | EP2773607B1 (https=) |
| JP (1) | JP6063472B2 (https=) |
| KR (1) | KR102336767B1 (https=) |
| CN (1) | CN103917514B (https=) |
| AU (1) | AU2012332111B2 (https=) |
| BR (1) | BR112014010584A2 (https=) |
| CA (1) | CA2853491C (https=) |
| EA (1) | EA027770B1 (https=) |
| ES (1) | ES2624427T3 (https=) |
| IL (1) | IL232452A (https=) |
| MX (1) | MX354653B (https=) |
| SG (1) | SG11201402056XA (https=) |
| WO (1) | WO2013067547A1 (https=) |
| ZA (1) | ZA201403003B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963475B2 (en) * | 2015-07-28 | 2018-05-08 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compound prodrugs and their uses |
| TW201718495A (zh) * | 2015-07-28 | 2017-06-01 | 貝塔貓製藥股份有限公司 | 蒽-9, 10-二酮二肟化合物前驅藥及其用途 |
| EP4656191A1 (en) * | 2017-06-02 | 2025-12-03 | Iterion Therapeutics, Inc. | Methods for treatment of fibrotic diseases |
| WO2019099836A1 (en) * | 2017-11-16 | 2019-05-23 | Northwestern University | Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases |
| WO2019229001A1 (en) * | 2018-05-30 | 2019-12-05 | Otto-Von-Guericke-Universität Magdeburg | Compounds for the treatment of jak2-v617f-associated cmn |
| CN119215047A (zh) * | 2024-10-11 | 2024-12-31 | 浙江大学 | 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2152258T (pt) * | 2007-05-10 | 2016-08-18 | Avalon Pharmaceuticals | Derivados de fluoreno, antraceno, xanteno, dibenzosuberona e acridina e suas utilizações |
| US8304408B2 (en) * | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| EA030302B1 (ru) * | 2008-11-21 | 2018-07-31 | Форест Лэборетериз Холдингз Лимитед | Антрахинондиоксимы и их применение |
| JP2013501792A (ja) * | 2009-08-10 | 2013-01-17 | サミュメッド リミテッド ライアビリティ カンパニー | Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用 |
| US20120157500A1 (en) * | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
| JP2013505968A (ja) | 2009-10-01 | 2013-02-21 | シーエスエル、リミテッド | フィラデルフィア染色体陽性白血病の治療方法 |
-
2012
- 2012-11-06 EP EP12845590.4A patent/EP2773607B1/en active Active
- 2012-11-06 BR BR112014010584A patent/BR112014010584A2/pt not_active IP Right Cessation
- 2012-11-06 AU AU2012332111A patent/AU2012332111B2/en active Active
- 2012-11-06 EA EA201490937A patent/EA027770B1/ru not_active IP Right Cessation
- 2012-11-06 CA CA2853491A patent/CA2853491C/en active Active
- 2012-11-06 JP JP2014540200A patent/JP6063472B2/ja active Active
- 2012-11-06 MX MX2014005498A patent/MX354653B/es active IP Right Grant
- 2012-11-06 KR KR1020147015141A patent/KR102336767B1/ko active Active
- 2012-11-06 CN CN201280054386.3A patent/CN103917514B/zh active Active
- 2012-11-06 US US13/670,377 patent/US9238030B2/en active Active
- 2012-11-06 WO PCT/US2012/063746 patent/WO2013067547A1/en not_active Ceased
- 2012-11-06 SG SG11201402056XA patent/SG11201402056XA/en unknown
- 2012-11-06 ES ES12845590.4T patent/ES2624427T3/es active Active
-
2014
- 2014-04-24 ZA ZA2014/03003A patent/ZA201403003B/en unknown
- 2014-05-04 IL IL232452A patent/IL232452A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201403003B (en) | 2017-08-30 |
| KR20140089418A (ko) | 2014-07-14 |
| NZ624446A (en) | 2016-01-29 |
| JP2014534229A (ja) | 2014-12-18 |
| EA201490937A1 (ru) | 2014-08-29 |
| EA027770B1 (ru) | 2017-08-31 |
| CA2853491C (en) | 2019-12-10 |
| KR102336767B9 (ko) | 2025-01-08 |
| BR112014010584A2 (pt) | 2017-05-02 |
| JP6063472B2 (ja) | 2017-01-18 |
| US20130143920A1 (en) | 2013-06-06 |
| AU2012332111B2 (en) | 2016-11-17 |
| CN103917514A (zh) | 2014-07-09 |
| KR102336767B1 (ko) | 2021-12-10 |
| IL232452A (en) | 2017-01-31 |
| IL232452A0 (en) | 2014-06-30 |
| ES2624427T3 (es) | 2017-07-14 |
| CN103917514B (zh) | 2016-11-16 |
| EP2773607A1 (en) | 2014-09-10 |
| WO2013067547A1 (en) | 2013-05-10 |
| EP2773607B1 (en) | 2017-03-29 |
| AU2012332111A1 (en) | 2014-05-22 |
| SG11201402056XA (en) | 2014-10-30 |
| HK1198440A1 (en) | 2015-04-24 |
| CA2853491A1 (en) | 2013-05-10 |
| US9238030B2 (en) | 2016-01-19 |
| EP2773607A4 (en) | 2015-03-11 |
| MX2014005498A (es) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| MX354653B (es) | Métodos para tratamiento de enfermedades y trastornos relacionados con la actividad de la proteína 1 similar a transducina b (tbl1), que incluyen la neoplasia mieloproliferativa y la leucemia mieloide crónica. | |
| EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
| EA202190619A1 (ru) | Противовирусные соединения | |
| CO6480975A2 (es) | Mimetico de smac | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| GEP20166438B (en) | Imidazopyrrolidinone compounds | |
| EA201490420A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С α-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ | |
| EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
| BR112014013526A8 (pt) | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados | |
| MX343561B (es) | Compuestos de imidazolpiridazina. | |
| UA113062C2 (xx) | Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону | |
| CU24265B1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer | |
| MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| EA201491391A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201290844A1 (ru) | Соединения для ингибирования иммунопротеасом | |
| EA201500574A1 (ru) | Новые инданилоксидигидробензофуранилуксусные кислоты | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| EA201300388A1 (ru) | Соединения замещенного бензамида | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| TR201815173T4 (tr) | Peptit bileşimleri. | |
| EA201590562A1 (ru) | Бензамиды | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| EA201301114A1 (ru) | Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент | |
| MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |